PW Medtech Group (FRA:PWE) Research & Development: €5.86 Mil (TTM As of Dec. 2025)


FRA:PWE PW Medtech Group Ltd FRA:PWE
82 GF Score
Price €0.11
GF Value €0.13
! 5 Warning Signs
View Full Analysis

What is PW Medtech Group Research & Development?

PW Medtech Group FRA:PWE 82 Research & Development is €5.86 Mil as of Dec. 2025. GuruFocus rates FRA:PWE with a GF Score™ of 82/100 and a GF Value™ of €0.13. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PW Medtech Group's Research & Development for the six months ended in Dec. 2025 was €3.14 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €5.86 Mil.

PW Medtech Group  (FRA:PWE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PW Medtech Group Research & Development Related Terms

PW Medtech Group Research & Development Historical Data

* Premium members only.

The historical data trend for PW Medtech Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PW Medtech Group Research & Development Chart

PW Medtech Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.81 5.55 5.28 5.79 5.87

PW Medtech Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 2.64 3.09 2.72 3.14
FRA:PWE
82GF Score
PW Medtech Group Ltd FRA:PWE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PW Medtech Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €5.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €5.86 Mil mean?
PW Medtech Group (FRA:PWE) has a Research & Development of €5.86 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on PW Medtech Group and its competitors.
Is PW Medtech Group's Research & Development too high?
PW Medtech Group's current Research & Development is €5.86 Mil. Overall, PW Medtech Group has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's Research & Development compare to ISRG and BDX?
PW Medtech Group's Research & Development of €5.86 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PW Medtech Group and its competitors. PW Medtech Group's current Research & Development is €5.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current Research & Development of €5.86 Mil. The stock's GF Value™ is €0.13, compared to a current price of €0.11 — trading 15.4% below its estimated fair value. The current Research & Development is €5.86 Mil. PW Medtech Group's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current Research & Development is €5.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PW Medtech Group (FRA:PWE) Overvalued in 2026?

Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued. The current stock price of €0.11 is trading 15.4% below its estimated GF Value™ of €0.13.

Key valuation signals for FRA:PWE:

  • Research & Development: €5.86 Mil
  • GF Value™: €0.13 vs. price of €0.11 (15.4% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PW Medtech Group Business Description

Other Exchanges 01358:Hong Kong
Address No. 23 Panlong West Road, Building 1, Pinggu District, Beijing, CHN, 101204
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
82GF Score

Get the complete analysis for FRA:PWE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.13
GF Value